Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
01 1Bachem AG
02 4Debiopharm Research & Manufacturing SA
03 1Synergy Health AST, Inc
04 3Synergy Health AST, LLC
01 2Triptorelin Pamoate
02 3Triptorelin pamoate
03 1triptorelin
04 3triptorelin pamoate
01 5Switzerland
02 4U.S.A
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0006
Start Marketing Date : 2006-06-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62788-288
Start Marketing Date : 2001-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (11.25mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-437
Start Marketing Date : 2010-10-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-715
Start Marketing Date : 2000-06-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION (3.75mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 62788-956
Start Marketing Date : 2017-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-103
Start Marketing Date : 2000-06-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-104
Start Marketing Date : 2001-06-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-105
Start Marketing Date : 2010-03-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71161-106
Start Marketing Date : 2017-09-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (22.5mg/2mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
55
PharmaCompass offers a list of Triptorelin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Triptorelin manufacturer or Triptorelin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Triptorelin manufacturer or Triptorelin supplier.
PharmaCompass also assists you with knowing the Triptorelin API Price utilized in the formulation of products. Triptorelin API Price is not always fixed or binding as the Triptorelin Price is obtained through a variety of data sources. The Triptorelin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Pamorelin LA manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pamorelin LA, including repackagers and relabelers. The FDA regulates Pamorelin LA manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pamorelin LA API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pamorelin LA manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pamorelin LA supplier is an individual or a company that provides Pamorelin LA active pharmaceutical ingredient (API) or Pamorelin LA finished formulations upon request. The Pamorelin LA suppliers may include Pamorelin LA API manufacturers, exporters, distributors and traders.
click here to find a list of Pamorelin LA suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pamorelin LA as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pamorelin LA API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pamorelin LA as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pamorelin LA and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pamorelin LA NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pamorelin LA suppliers with NDC on PharmaCompass.
We have 3 companies offering Pamorelin LA
Get in contact with the supplier of your choice:
